The authorisation comes three months after the MHRA approved Johnson & Johnson’s Lazcluze (lazertinib), which is also ...

Biocartis’ Idylla EGFR Mutation Test has secured the EU Technical Documentation Assessment and Quality Management System ...

Patritumab deruxtecan treatment did not improve suvival end points versus those treated with chemotherapy in EGFR+ ...

Helena Yu, MD, discusses the efficacy of zipalertinib for EGFR-mutant non–small cell lung cancer and the importance of ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', 6990.HK) today announced that results from its ...

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

In a recent study, researchers have uncovered the biological trigger behind the dangerous immune-related adverse events ...

CEST Biocartis Announces IVDR Class C CDx Certification of the Idylla™ EGFR Mutation Test Mechelen, Belgium, 02 June 2025 – ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

Patients with stage II and IIIB non-small cell lung cancer (NSCLC) with an EGFR mutation had better outcomes when treated ...

The use of tyrosine kinase inhibitors (TKIs) in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) has not produced the same durable clinical benefits ...

In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab ...